Astellas Tacrolimus Approval Remains At Bay
This article was originally published in The Pink Sheet Daily
Executive Summary
On heels of second “approvable” letter for kidney transplant rejection, FDA issues another approvable for liver indication.
You may also be interested in...
Astellas Finally Wins FDA Approval For Prograf Successor
Female mortality rate among liver transplant patients had been a major obstacle to approval for extended-release tacrolimus, which was first filed in 2005. But the once-daily drug is now approved for kidney transplant patients.
Astellas Announces 32 Percent Earnings Increase For Fiscal 2007
Tokyo firm anticipates 10.4 percent drop in fiscal 2008 with Prograf patent expiry.
Astellas Announces 32 Percent Earnings Increase For Fiscal 2007
Tokyo firm anticipates 10.4 percent drop in fiscal 2008 with Prograf patent expiry.